Cue Biopharma Presents Updated Data from Phase 1 Trial of CUE-101 in Recurrent/Metastatic HPV+ Head and Neck Cancer at the 2024 ASCO Annual Meeting
Stock Information for Cue Biopharma Inc.
Loading
Please wait while we load your information from QuoteMedia.